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ABSTRACT
Insulin hypersensitivity—a rare occurrence with
currently available insulin preparations—may
have varied manifestations, ranging from a local
injection site allergy to severe generalized
anaphylactic reactions. While various additives
included in commercial insulin preparations
and insulin peptides themselves remain the
primary allergens responsible, faulty injection
technique may at times potentiate the
development of insulin allergy. Management
of insulin allergy is complex, potentially
dangerous at times, and can be challenging for
the treating physician. We report a case of
insulin allergy due to intradermal insulin
injections which was cured by adopting a
proper injection technique.
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INTRODUCTION
Hypersensitivity to insulin preparations,
ranging from a minor local injection site
allergy to severe generalized and at times
life-threatening anaphylactic reactions,
currently affects \4% of diabetic patients
treated with insulin [1]. The insulin peptide
itself and the various additives present in the
formulations are proposed to be the allergens
responsible. A faulty injection technique and
the resulting intradermal insulin
administration can facilitate the development
of such allergic reactions.
CASE REPORT
A 65-year-old gentleman (body mass index
32.2 kg/m2) with a 10-year history of type 2
diabetes presented with a month-long history of
burning sensation followed by appearance of a
pruritic maculopapular rash in and around the
injection site within half an hour after insulin
administration. He had been using oral
antihistaminics and topical steroids for
symptomatic relief during the previous two
weeks without much effect while the rash kept
appearing after each shot of insulin
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administered. Frustrated with the repetitive
allergic reactions, he became desperate to find
an effective noninjectable antidiabetic
medication. However, due to low stimulated
C-peptide levels (0.4 ng/ml), his primary care
physician insisted on continuation of the
existing insulin therapy, which led him to
omit the scheduled doses of insulin in a
desperate attempt to avoid unpleasant local
adverse reactions. Three months prior to this
presentation he had been prescribed a
twice-daily premixed human insulin (30%
regular and 70% neutral protamine Hagedorn)
in view of sustained poor glycemic control with
optimal dosage of oral antidiabetic drugs.
During the initial 2 months, his daughter used
to inject insulin into his anterior abdomen after
being taught how to perform insulin injection
by the care giver. During that period, the
injections were virtually painless, and the
patient noticed satisfactory glycemic control
without any skin changes around the injection
site. However, with the marriage of his daughter
he had started to self-inject himself and noticed
development of an itchy rash after each and
every injection. He did not experience itching
on other body parts, or any cough, wheeze, or
shortness of breath.
Examination of the injection sites revealed
two long-standing keloid scars with multiple
tender violaceous maculopapular rashes all over
the anterior abdomen (Fig. 1). Baseline
investigations (including a complete blood
count, renal function test, liver function test,
lipid profile, electrolytes, chest X-ray, and ECG)
were normal except for an elevated absolute
eosinophil count (982/cmm) and a mildly
elevated serum IgE level [121.2 IU/ml
(reference: 1–87 IU/ml)]. The urine spot
albumin–creatinine ratio (ACR) was 178 mg/
gm and the HbA1c was 9% on an NGSP allied
assay. His detailed history revealed that he had
been using a U-40 insulin syringe with a needle
length of 4 mm and inserting the needle
horizontally (at less than 15) with respect to
the plane of skin fold. With every faulty
injection, he experienced significant pain and
noticed the development of a small bleb over
the application site. The faulty injection
technique, new-onset pain, and the
appearance of an intradermal bleb over the
injection site was suggestive of intradermal
insulin administration instead of subcutaneous
administration. He had no family history of
allergy or atopy, and he could not recollect any
Fig. 1 Multiple violaceous maculopapular rashes on the abdomen following insulin injections. Two long-standing keloids
(solid black arrow) are also apparent
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form of local or systemic allergic reaction to a
particular agent in the past.
The insulin injection technique was rectified
and the patient was advised to have a skin
biopsy, which he declined. However, all of the
rashes disappeared completely after 2 weeks and
the patient did not notice similar symptoms
after adopting the proper injection technique
(Fig. 2).
Causality analysis for intradermal insulin
injection and the allergic cutaneous lesions
was performed using the World Health
Organization–Uppsala Monitoring Centre
(WHO-UMC) causality assessment scale and
the Naranjo adverse drug reaction probability
scale, and it was found that intradermal
injection was the probable cause of the
adverse drug reaction [probable/likely on the
WHO-UMC causality assessment scale and
probable (total score 8) on the Naranjo
probability scale].
DISCUSSION
The frequency of allergic reactions to insulin
has declined significantly since the
introduction of human recombinant insulin
and insulin analogs into clinical practice. A
common occurrence during the era of animal
insulins because of altered peptide structures,
presence of contaminants, highly
immunogenic components such as C-peptide
and proinsulin and the resulting greater
antigenic potential, hypersensitivity reactions
are now usually due to the presence of various
pharmaceutical formula additives (protamine,
meta-cresol, phenol, sodium phosphate, zinc,
etc.) [2]. However, human insulin and insulin
analogs can also act as potential allergens at
times, and this has been observed with almost
all currently available insulins. Insulin allergies
can be local or systemic, as well as immediate or
delayed. The underlying mechanisms of
insulin-associated allergy can be divided into
three types: type I (IgE-mediated), type III
(IgG-mediated immune complex), and type IV
(T-cell-mediated delayed-type) hypersensitivity.
Type I hypersensitivity, which manifests as local
edema, itching, wheals, and flares, is the most
common form [3].
Various treatment options, ranging from
symptom relief using simple antihistaminics to
more complicated insulin desensitization
therapy, have been advocated for managing
allergic reactions to insulin [1, 3]. Though
systemic corticosteroids can be used for
Fig. 2 Complete disappearance of the allergic rashes after adopting the proper injection technique
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symptom relief, they aggravate hyperglycemia,
and changing the insulin to oral hypoglycemic
agents may not possible in cases of type 1 or a
long-standing insulinopenic spectrum of type 2
diabetes, as in this patient. Changing the
insulin preparation to another preparation has
also been used with success due to subtle
differences in amino acid sequences and
antigenicities between different insulins [4, 5].
Epidermal Langerhans cells acting as
antigen-presenting cells transport foreign
antigen to T lymphocytes and play a pivotal
role in the initiation of cutaneous immune
responses, including immune responses to
chemical allergens encountered at skin surfaces.
The development of insulin allergy following
intradermal insulin administration may be
explained by easy and extensive availability of
antigens to resident Langerhans cells in the
epidermis and subsequent augmentation of a
localized immune response [6].
CONCLUSION
Though faulty injection technique is a simple
and easily treatable cause of injection site
allergy in insulin-treated diabetics, it is often
overlooked in clinical practice. To the best of
our knowledge, such an association has rarely
been described in the global literature [7]. To
conclude, treating physicians should enquire
about injection technique when managing
patients with an insulin allergy, as this may
avoid the need to explore other costly,
complicated, and potentially dangerous
treatment alternatives.
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